alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<PAGE>

EXHIBIT 32 (a)

      CERTIFICATION PURSUANT TO 18 U.S.C SECTION 1350, AS ADOPTED PURSUANT
                TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Northland Cable Properties Seven
Limited Partnership (the "Partnership") on Form 10Q for the period ended March
31, 2006 as filed with the Securities and Exchange Commission on the date hereof
(the "Form 10-Q"), I, John Whetzell, Chief Executive Officer of Northland
Communications Corporation, the General Partner, certify, pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002, that;

      (1)   The Form 10-Q fully complies with the requirements of Section 13 (a)
            or (15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or
            78(d)); and

      (2)   The information contained in the Form 10-Q fairly presents in all
            material respects, the financial condition and results of operations
            of the Partnership.

DATE: 5-11-06

/s/ JOHN S. WHETZELL
----------------------------------------
    John S. Whetzell
    Chief Executive Officer

A signed original of this written statement required by Section 906 has been
provided to Northland Cable Properties Seven Limited Partnership and will be
retained by Northland Cable Properties Seven Limited Partnership and furnished
to the Securities and Exchange Commission or its staff upon request.
**Exhibit 32.1**

 

**CERTIFICATIONPURSUANT TO18 U.S.C. SECTION 1350,AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

 

In connection with theQuarterly Report on Form 10-Q for the fiscal quarter ended June 30,2005 of Spescom Software Inc. (the “Company”) as filed with the Securities andExchange Commission on the date hereof (the “Report”), each of the undersignedhereby certifies, in his capacity as an officer of the Company, for purposes of18 U.S.C.  Section 1350, as adoptedpursuant to Section 906 of the Sarbanes-Oxley Act of 2002,that based on his knowledge:

 

1.               The Report fullycomplies with the requirements of Section 13(a) or 15(d) of theSecurities Exchange Act of 1934; and

 

2.               The informationcontained in the Report fairly presents, in all material respects, thefinancial condition and results of operations of the Company.

 
|   | August 15, 2005        |
|--------|-----------------------------|
|   |                        |
|   | /s/ Carl Mostert            |   |
|   | Carl Mostert                |
|   | Chief Executive Officer  of |
|   | Spescom Software Inc.       |
|   |                        |
|   |                        |
|   | /s/ John W. Low             |   |
|   | John W. Low                 |
|   | Chief Financial Officer  of |
|   | Spescom Software Inc.       |

 

A signed original of thiswritten statement required by Section 906, or other documentauthenticating, acknowledging, or otherwise adopting the signature that appearsin typed form within the electronic version of this written statement requiredby Section 906, has been provided to Spescom Software Inc. and will beretained by Spescom Software Inc. and furnished to the Securities and ExchangeCommission or its staff upon request.

 

----
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
CONSOLIDATED BALANCE SHEET AND CONSOLIDATED STATEMENT OF OPERATIONS FOUND ON
PAGES 3 AND 4 OF THE COMPANY'S FORM 10-Q FOR THE YEAR-TO-DATE MARCH 31, 1997 AND
IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-END>                               MAR-31-1997
<CASH>                                           1,440
<SECURITIES>                                         0
<RECEIVABLES>                                   10,882
<ALLOWANCES>                                         0
<INVENTORY>                                        447
<CURRENT-ASSETS>                                13,647
<PP&E>                                           7,381
<DEPRECIATION>                                   5,306
<TOTAL-ASSETS>                                  23,421
<CURRENT-LIABILITIES>                            6,395
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        61,630
<OTHER-SE>                                    (46,391)
<TOTAL-LIABILITY-AND-EQUITY>                    23,421
<SALES>                                          6,615
<TOTAL-REVENUES>                                 6,615
<CGS>                                            2,871
<TOTAL-COSTS>                                    2,871
<OTHER-EXPENSES>                                   812
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                (51)
<INCOME-PRETAX>                                    534
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                534
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                       534
<EPS-PRIMARY>                                      .06
<EPS-DILUTED>                                      .06
        

</TABLE>
Consent of Independent Auditors

We consent to the incorporation by reference in the Registration Statement
(Form S-8 No. 33-66964)  pertaining to the 1992 Non-employee Director Stock
Option Plan and 1992 Stock Option Plan of Concepts Direct, Inc. of our
report dated February 19, 1998, with respect to the financial statements and
schedule II of Concepts Direct, Inc. included in its Annual Report (Form
10-K) for the year ended December 31, 1997, filed with the Securities and
Exchange Commission.

/s/ Ernst & Young
    Denver, Colorado
    March 13, 1998
I 

118TH CONGRESS 

1ST SESSION H. R. 723 

To amend the Food and Nutrition Act of 2008 to require States to include 

a photograph on electronic benefit cards issued to provide supplemental 

nutrition assistance program benefits. 

IN THE HOUSE OF REPRESENTATIVES 

FEBRUARY 1, 2023 

Mr. GROTHMAN (for himself and Mr. TIFFANY) introduced the following bill; 

which was referred to the Committee on Agriculture 

A BILL 

To amend the Food and Nutrition Act of 2008 to require 

States to include a photograph on electronic benefit cards 

issued to provide supplemental nutrition assistance program benefits. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘ID for EBT Act of 

5 2023’’. 

6 SEC. 2. AMENDMENTS. 

7 Section 7(h)(9) of the Food and Nutrition Act of 

8 2008 (7 U.S.C. 2016(h)(9)) is amended— 


pbinns on DSKJLVW7X2PROD with $$_JOB
2 

•HR 723 IH

1 (1) in the heading by striking ‘‘OPTIONAL’’ and 

2 inserting ‘‘MANDATORY’’; 

3 (2) in subparagraph (A) by striking ‘‘may’’ and 

4 inserting ‘‘shall’’; and 

5 (3) in subparagraph (B) by striking ‘‘If’’ and 

6 all that follows through ‘‘(A), the’’ and inserting 

7 ‘‘The’’. 

8 SEC. 3. EFFECTIVE DATE. 

9 This Act and the amendments made by this Act shall 

10 take effect 180 days after the date of the enactment of 

11 this Act. 

Æ 


pbinns on DSKJLVW7X2PROD with $$_JOB
EXHIBIT 32.2



CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350

Pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, I, David H. Thompson, Secretary and Chief Financial Officer of International Absorbents Ins., certify that:

1.

To my knowledge, this report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and



2.

To my knowledge, the information in this report fairly presents, in all material respects, the financial condition and results of operations of International Absorbents Inc. as of October 31, 2008.



|                            |     |                                      
|--------------------------- | --- | -------------------------------------
|Date:     December 15, 2008 | By: | /s/ DAVID H. THOMPSON                
|                            |     | David H. Thompson                    
|                            |     | Secretary and Chief Financial Officer
Editorial Note on Part 316
Editorial Note: Nomenclature changes to part 316 appear at 69 FR 13717, Mar. 24, 2004.

§ 316.1 Scope of this part. ( a ) This part implements sections 525, 526, 527, and 528 of the act and provides procedures to encourage and facilitate the development of drugs for rare diseases or conditions, including biological products and antibiotics. This part sets forth the procedures and requirements for: ( 1 ) Submissions to FDA of: ( i ) Requests for recommendations for investigations of drugs for rare diseases or conditions;
( ii ) Requests for designation of a drug for a rare disease or condition; and
( iii ) Requests for gaining exclusive approval for a drug for a rare disease or condition.
( 2 ) Allowing a sponsor to provide an investigational drug under a treatment protocol to patients who need the drug for treatment of a rare disease or condition.
( b ) This part does not apply to food, medical devices, or drugs for veterinary use.
( c ) References in this part to regulatory sections of the Code of Federal Regulations are to chapter I of title 21, unless otherwise noted.
[57 FR 62085, Dec. 29, 1992, as amended at 78 FR 35132, June 12, 2013]
Editorial Note on Part 189
Editorial Note: Nomenclature changes to part 189 appear at 61 FR 14482, Apr. 2, 1996; 66 FR 56035, Nov. 6, 2001; 70 FR 40880, July 15, 2005; and 70 FR 67651, Nov. 8, 2005.

§ 189.250 Mercaptoimidazoline and 2-mercaptoimidazoline. ( a ) Mercaptoimidazoline and 2-mercaptoimidazoline both have the molecular formula C3H6N2S. They are synthetic chemicals not found in natural products and have been used in the production of rubber articles that may come into contact with food.
( b ) Food containing any added or delectable levels of these substances is deemed to be adulterated in violation of the act based upon an order published in the Federal Register of November 30, 1973 (38 FR 33072).
Editorial Note on Part 184
Editorial Note: Nomenclature changes to part 184 appear at 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 69 FR 13717, Mar. 24, 2004; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; and 81 FR 49897, July 29, 2016.

§ 184.1024 Bromelain. ( a ) Bromelain (CAS Reg. No. 9001-00-7) is an enzyme preparation derived from the pineapples *Ananas comosus* and *A. bracteatus* L. It is a white to light tan amorphous powder. Its characterizing enzyme activity is that of a peptide hydrolase (EC 3.4.22.32).
( b ) The ingredient meets the general requirements and additional requirements for enzyme preparations in the Food Chemicals Codex, 3d ed. (1981), p. 110, which is incorporated by reference in accordance with 5 U.S.C. 552(a) and 1 CFR part 51. Copies are available from the National Academy Press, 2101 Constitution Ave. NW., Washington, DC, or may be examined at Office of Food Additive Safety (HFS-200), Center for Food Safety and Applied Nutrition, Food and Drug Administration, 5001 Campus Dr., College Park, MD 20740, 240-402-1200, and at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030, or go to: *http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html .*
( c ) In accordance with § 184.1(b)(1), the ingredient is used in food with no limitation other than current good manufacturing practice. The affirmation of this ingredient as GRAS as a direct food ingredient is based upon the following current good manufacturing practice conditions of use: ( 1 ) The ingredient is used as an enzyme as defined in § 170.3(o)(9) of this chapter to hydrolyze proteins or polypeptides.
( 2 ) The ingredient is used in food at levels not to exceed current good manufacturing practice.
[60 FR 32910, June 26, 1995, as amended at 78 FR 14666, Mar. 7, 2013]
§ 211.167 Special testing requirements. ( a ) For each batch of drug product purporting to be sterile and/or pyrogen-free, there shall be appropriate laboratory testing to determine conformance to such requirements. The test procedures shall be in writing and shall be followed.
( b ) For each batch of ophthalmic ointment, there shall be appropriate testing to determine conformance to specifications regarding the presence of foreign particles and harsh or abrasive substances. The test procedures shall be in writing and shall be followed.
( c ) For each batch of controlled-release dosage form, there shall be appropriate laboratory testing to determine conformance to the specifications for the rate of release of each active ingredient. The test procedures shall be in writing and shall be followed.
<TABLE> <S> <C>

<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-END>                               SEP-30-1997
<CASH>                                               0
<SECURITIES>                                         0
<RECEIVABLES>                               14,110,825
<ALLOWANCES>                                 (355,864)
<INVENTORY>                                 15,323,763
<CURRENT-ASSETS>                            34,176,331
<PP&E>                                       6,718,996
<DEPRECIATION>                             (3,002,408)
<TOTAL-ASSETS>                              58,717,669
<CURRENT-LIABILITIES>                       13,884,501
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                    25,711,782
<OTHER-SE>                                 (4,400,618)
<TOTAL-LIABILITY-AND-EQUITY>                58,717,669
<SALES>                                     36,534,345
<TOTAL-REVENUES>                            36,981,081
<CGS>                                       13,592,340
<TOTAL-COSTS>                               13,592,340
<OTHER-EXPENSES>                            21,784,878
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                           1,178,289
<INCOME-PRETAX>                                425,574
<INCOME-TAX>                                    86,000
<INCOME-CONTINUING>                            339,574
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   339,574
<EPS-PRIMARY>                                     0.04
<EPS-DILUTED>                                        0
        

</TABLE>
Exhibit 4.18


 


AMENDMENT TO BINDING Term
Sheet


 


Dated
February 9, 2017


 


[unofficial
translation from hebrew to english]


 


The agreements attached to
this email are agreed upon by the Parties thereto as the final drafts thereof. Annex A to the document entitled “Binding
Term Sheet” is amended as follows:


 


The amount
$775 in Section 3.1 and the amount $595 in Section 3.2 of Annex A, will be replaced by such number which is equal to US$ 13,500,000
divided by the issued and outstanding share capital of the Company as of today’s date of this Agreement (February 9th
2017).


 


The amendment is agreed upon
by all Parties.


 


/s/ Ran Streichman


 



 


For:


TAOZ – COMPANY FOR MANAGEMENT 


AND HOLDINGS OF COMPANIES LTD.


 


 


/s/ Ran Diamant, Adv.


 



 


For:


KITOV PHARMACEUTICALS HOLDINGS LTD.  &
TYRNOVO Ltd.
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from Balance
Sheet, Statement of Operations, Statements of Cash Flows and Notes thereto
incorporated in Part I, Item 1. of this Form 10QSB and is qualified in its
entirety by reference to such financial statements.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-END>                               SEP-30-1998
<CASH>                                          28,985
<SECURITIES>                                         0
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                28,985
<PP&E>                                               0
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                                  28,985
<CURRENT-LIABILITIES>                                0
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        47,400
<OTHER-SE>                                           0
<TOTAL-LIABILITY-AND-EQUITY>                    28,985
<SALES>                                              0
<TOTAL-REVENUES>                                     0
<CGS>                                                0
<TOTAL-COSTS>                                    2,015
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                (2,015)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (2,015)
<EPS-BASIC>                                     0.00
<EPS-DILUTED>                                     0.00


</TABLE>
### FDMS Do **cket No. FAA -**  **2012 -**  **004 1**  **Contacts.** With whom outside the FAA has this proposal been discussed?

Organization Person Contacted Date Response National Business Aircraft Association Eli Cotti 6/2 3 /11 Regional Airline Association Co nnie Arnold 6/2 3 /11

Aircraft Owners & Pilots Association Robert Hackman 6/2 3 /11 AT A Joe White 6/2 3 /11
###### Editorial Note on Part 177

#### Editorial Note:

Nomenclature changes to part 177 appear at 61 FR 14482, Apr. 2, 1996; 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 70 FR 72074, Dec. 1, 2005; and 81 FR 49896, July 29, 2016.

#### § 177.1850 Textryls.

Textryls identified in this section may be safely used as articles or components of articles, intended for use in producing, manufacturing, packing, processing, preparing, treating, packaging, transporting or holding food, subject to the provisions of this section.

(a) Textryls are nonwoven sheets prepared from natural or synthetic fibers, bonded with fibryl (Fibryl consists of a polymeric resin in fibrous form commingled with fiber to facilitate sheet formation and subsequently heat cured to fuse the fibryl and effect bonding).

(b) Textryls are prepared from the fibers, fibryls, and adjuvants identified in paragraph (c) of this section, and subject to limitations prescribed in that paragraph, provided that any substance that is the subject of a regulation in parts 174, 175, 176, 177, 178 and § 179.45 of this chapter conforms with any specifications in such regulation for that substance as a component of polymeric resins used as food contact surfaces.

(c) The fibers, fibryls, and adjuvants permitted are as follows:

| Substances | Limitations |
| --- | --- |
| (1) Fibers prepared from polyethylene terephthalate resins | Conforming with § 177.1630. |
| (2) Fibryls prepared from vinyl chloride-vinyl acetate copolymer | As the basic polymer. |
| (3) Adjuvant substance, dimethylformamide | As a solvent in the preparation of fibryl. |

(d) Textryls meeting the conditions of test prescribed in paragraph (d)(1) of this section are used as prescribed in paragraph (d)(2) of this section.

(1) *Conditions of test.* Textryls, when extracted with distilled water at reflux temperature for 1 hour, yield total extractives not to exceed 1 percent.

(2) *Uses.* Textryls are used for packaging or holding food at ordinary temperatures and in the brewing of hot beverages.
# LI2019179EN.01000201.xml

| 3.7.2019 | EN | Official Journal of the European Union | LI 179/2 |
| --- | --- | --- | --- |

3.7.2019

EN

Official Journal of the European Union

LI 179/2

---

EUROPEAN COUNCIL DECISION (EU) 2019/1136

of 2 July 2019

proposing to the European Parliament a candidate for President of the European Commission

THE EUROPEAN COUNCIL,

Having regard to the Treaty on European Union, and in particular Article 17(7) thereof,

Whereas:

| (1) | Article 17(7) of the Treaty on European Union provides that, taking into account the elections to the European Parliament and after having held the appropriate consultations, the European Council proposes to the European Parliament a candidate for President of the European Commission. |
| --- | --- |

(1)

Article 17(7) of the Treaty on European Union provides that, taking into account the elections to the European Parliament and after having held the appropriate consultations, the European Council proposes to the European Parliament a candidate for President of the European Commission.

| (2) | The elections to the European Parliament were held between 23 and 26 May 2019, in accordance with Council Decision (EU, Euratom) 2018/767 (1). |
| --- | --- |

(2)

The elections to the European Parliament were held between 23 and 26 May 2019, in accordance with Council Decision (EU, Euratom) 2018/767 (1).

| (3) | In accordance with Declaration No 11 annexed to the Final Act of the Intergovernmental Conference which adopted the Treaty of Lisbon, representatives of the European Parliament and of the European Council conducted the necessary consultations. |
| --- | --- |

(3)

In accordance with Declaration No 11 annexed to the Final Act of the Intergovernmental Conference which adopted the Treaty of Lisbon, representatives of the European Parliament and of the European Council conducted the necessary consultations.

| (4) | Therefore a candidate should be proposed to the European Parliament for President of the European Commission, |
| --- | --- |

(4)

Therefore a candidate should be proposed to the European Parliament for President of the European Commission,

HAS ADOPTED THIS DECISION:

Article 1

Ms Ursula VON DER LEYEN is hereby proposed to the European Parliament as candidate for President of the European Commission.

Article 2

This Decision shall be forwarded to the European Parliament.

Article 3

This Decision shall be published in the Official Journal of the European Union.

Done at Brussels, 2 July 2019.

For the European Council

The President

D. TUSK

---

(1)  Council Decision (EU, Euratom) 2018/767 of 22 May 2018 fixing the period for the ninth election of representatives to the European Parliament by direct universal suffrage (OJ L 129, 25.5.2018, p. 76).

1

---